DBV TECHNOLOGIE/S (NASDAQ:DBVT) Raised to Hold at BidaskClub

BidaskClub upgraded shares of DBV TECHNOLOGIE/S (NASDAQ:DBVT) from a sell rating to a hold rating in a research report report published on Thursday, BidAskClub reports.

Several other research firms have also recently weighed in on DBVT. Zacks Investment Research cut shares of DBV TECHNOLOGIE/S from a buy rating to a hold rating in a research report on Tuesday, August 6th. Goldman Sachs Group initiated coverage on shares of DBV TECHNOLOGIE/S in a research report on Monday, June 17th. They set a buy rating and a $14.00 price objective for the company. Finally, ValuEngine raised shares of DBV TECHNOLOGIE/S from a hold rating to a buy rating in a research report on Thursday, August 1st. One analyst has rated the stock with a sell rating, six have issued a hold rating and five have issued a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus price target of $14.81.

NASDAQ:DBVT opened at $8.98 on Thursday. DBV TECHNOLOGIE/S has a 1-year low of $3.60 and a 1-year high of $25.77. The company has a current ratio of 3.34, a quick ratio of 3.30 and a debt-to-equity ratio of 0.01. The firm has a fifty day simple moving average of $9.63 and a 200 day simple moving average of $8.78. The stock has a market capitalization of $528.97 million, a PE ratio of -2.65 and a beta of 1.82.

Hedge funds have recently added to or reduced their stakes in the business. Quantamental Technologies LLC boosted its position in DBV TECHNOLOGIE/S by 63.9% during the first quarter. Quantamental Technologies LLC now owns 4,917 shares of the company’s stock worth $38,000 after purchasing an additional 1,917 shares during the period. FNY Investment Advisers LLC bought a new stake in shares of DBV TECHNOLOGIE/S in the second quarter valued at about $102,000. LeJeune Puetz Investment Counsel LLC bought a new stake in shares of DBV TECHNOLOGIE/S in the second quarter valued at about $108,000. Cubist Systematic Strategies LLC boosted its position in shares of DBV TECHNOLOGIE/S by 10.2% in the second quarter. Cubist Systematic Strategies LLC now owns 13,284 shares of the company’s stock valued at $109,000 after acquiring an additional 1,229 shares during the period. Finally, Bank of Montreal Can bought a new stake in shares of DBV TECHNOLOGIE/S in the first quarter valued at about $113,000. 46.37% of the stock is owned by hedge funds and other institutional investors.

DBV TECHNOLOGIE/S Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.

Further Reading: CD Ladder

Analyst Recommendations for DBV TECHNOLOGIE/S (NASDAQ:DBVT)

Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.